Gleevec approved in Canada

Canada granted marketing approval to Novartis (NVS; SWX:NOVN) for its Gleevec imatinib Bcr-Abl inhibitor to treat chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase after fai...